Experimental combo targets Chemo-Resistant cancers
NCT ID NCT03476681
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe dose and see if the combination can shrink tumors or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
INOVA Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
National Cancer Institute
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NEO-201 (an experimental antibody) combined with pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with certain advanced cancers that no longer respond to standard therapy.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. The combination may cause significant side effects, and not all patients may respond.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.